Celgene Co. (CELG) Holdings Reduced by Investment House LLC

Investment House LLC lowered its stake in Celgene Co. (NASDAQ:CELG) by 20.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 56,493 shares of the biopharmaceutical company’s stock after selling 14,146 shares during the quarter. Investment House LLC’s holdings in Celgene were worth $5,056,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of CELG. Ayalon Holdings Ltd. acquired a new position in Celgene in the second quarter valued at about $100,000. Atlantic Trust LLC purchased a new stake in Celgene during the second quarter worth about $101,000. Acropolis Investment Management LLC purchased a new stake in Celgene during the second quarter worth about $112,000. Moneta Group Investment Advisors LLC increased its stake in Celgene by 2,688.6% during the second quarter. Moneta Group Investment Advisors LLC now owns 10,290 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 9,921 shares during the period. Finally, City Holding Co. purchased a new stake in Celgene during the second quarter worth about $143,000. 73.11% of the stock is currently owned by institutional investors.

A number of analysts have issued reports on CELG shares. Zacks Investment Research lowered shares of Celgene from a “hold” rating to a “sell” rating in a research note on Wednesday, July 18th. Mizuho reiterated a “buy” rating and set a $129.00 price target on shares of Celgene in a research note on Tuesday, July 31st. BidaskClub lowered shares of Celgene from a “buy” rating to a “hold” rating in a research note on Thursday, September 13th. Morgan Stanley boosted their price target on shares of Celgene from $91.00 to $93.00 and gave the stock an “equal weight” rating in a research note on Friday, July 27th. Finally, Standpoint Research upgraded shares of Celgene from a “hold” rating to a “buy” rating in a research note on Monday, June 18th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company. Celgene has a consensus rating of “Buy” and an average price target of $121.42.

In related news, Director John H. Weiland purchased 5,575 shares of the company’s stock in a transaction on Tuesday, August 7th. The shares were bought at an average cost of $89.73 per share, for a total transaction of $500,244.75. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ernest Mario sold 12,000 shares of the stock in a transaction that occurred on Thursday, August 9th. The shares were sold at an average price of $92.32, for a total transaction of $1,107,840.00. Following the completion of the transaction, the director now owns 44,413 shares in the company, valued at $4,100,208.16. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by corporate insiders.

Shares of CELG stock traded down $0.30 during trading hours on Tuesday, reaching $87.19. 37,226 shares of the stock were exchanged, compared to its average volume of 6,537,472. The company has a debt-to-equity ratio of 5.76, a quick ratio of 1.40 and a current ratio of 1.52. Celgene Co. has a 12-month low of $74.13 and a 12-month high of $140.20. The firm has a market capitalization of $62.94 billion, a price-to-earnings ratio of 12.76, a PEG ratio of 0.54 and a beta of 1.30.

Celgene (NASDAQ:CELG) last released its earnings results on Thursday, July 26th. The biopharmaceutical company reported $2.16 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.05. Celgene had a net margin of 19.81% and a return on equity of 87.28%. The firm had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.70 billion. During the same period in the prior year, the firm earned $1.82 earnings per share. The business’s quarterly revenue was up 16.6% compared to the same quarter last year. Equities analysts forecast that Celgene Co. will post 7.64 EPS for the current fiscal year.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

See Also: Trading Strategy Methods and Types

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply